Koninklijke Philips Corporation N.V.

Other

University of Glasgow

Innosign B.v.

Ralf Hoffmann

Marcia Alves De Inda

Miles Douglas Houslay

David James Peter Henderson

Dimitrios Mavroeidis

Jacek Lukasz Kustra

Helga Hummel

Sergio Consoli

Monique Hendriks

Dianne Arnoldina Margaretha Wilhelmina Van Strijp

Anne Godefrida Catharina Van Brussel

Pieter Christiaan Vos

Janneke Wrobel

Johan Janssen

Eveline Den Biezen-Timmermans

Wilhelmus Franciscus Johannes Verhaegh

Volker Weiler

Anja Van De Stolpe

Joannes Baptist Adrianus Dionisius Van Zon

Carolina Ribbing

Peter Klaus Bachmann

Lothar Spies

Hendrik Jan Van Ooijen

Kalyana Chakravarthi Dulla

Juergen Breitlow-Hertzfeldt

Johannes Baptist Adrianus Dionisius Van Zon

Erich Windhab

Carl Hoyer

Friedrich H Rogge

Ulrich Fels

Lutz Hahn

Peter Von Holdt

The invention provides a method for evaluating a set of input data, the input data comprising at least one of: clinical data of a subject; genomic data of a subject; clinical data of a plurality of subjects; and genomic data of a plurality of subjects, using a deep learning algorithm. The method includes obtaining a set of input data, wherein the set of input data comprises raw data arranged into a plurality of data clusters and tuning the deep learning algorithm based on the plurality of data clusters. The deep learning algorithm comprises: an input layer; an output layer; and a plurality of hidden layers. The method further includes performing statistical clustering on the raw data using the deep learning algorithm, thereby generating statistical clusters and obtaining a marker from each statistical cluster. Finally, the set of input data is evaluated based on the markers to derive data of medical relevance in respect of the subject or subjects.

Evaluating input data using a deep learning algorithm

The invention relates to a method of pre-surgical risk stratification of a prostate cancer subject, comprising determining a gene expression profile for phosphodiesterase 4D variant 7 (PDE4D7) in a biological sample obtained from the subject, determining gene expression profile, and determining a pre-surgical prognostic risk score for the subject based on the expression based risk score and pre-surgical clinical variables of the subject. This may allow for an improved stratification of the subject in a pre-surgical setting that may result in better primary treatment decisions. For instance, the pre-surgical prognostic risk score may allow to make better recommendation on whether to select active surveillance vs. active intervention, e.g., radical prostatectomy, for certain sub-populations of prostate cancer patients.

Pre-surgical risk stratification based on PDE4D7 expression and pre-surgical clinical variables

The present invention relates to methods for diagnosing, monitoring or prognosticating prostate cancer or the progression state of prostate cancer wherein said method determines the state of the prostate cancer, based on the expression level of phosphodiesterase 4D (PDE4D) variants. The invention further relates to a method of identifying an individual for eligibility for prostate cancer therapy. The invention also relates to products for the analysis of phosphodiesterase 4D (PDE4D) variants as well as pharmaceutical compositions modulating the activity and/or expression of PDE4D variants.

Methods of prostate cancer prognosis

The present application mainly relates to specific methods for inferring activity of one or more cellular signaling pathway(s) in tissue of a medical subject based at least on the expression level(s) of one or more target gene(s) of the cellular signaling pathway(s) measured in an extracted sample of the tissue of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods.

Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression

Methods are described for stratifying patient risk for patients with prostate cancer and for providing a treatment recommendation to a patient based on a phosphodiesterase 4D variant 7 (PDE4D7) risk score. A diagnostic kit and a computer program product for the analysis and determination of the PDE4D7 risk score are also described.

Risk scores based on human phosphodiesterase 4D variant 7 expression

The present invention relates to phosphodiesterase 9A (PDE9A) for use as a marker for prostate cancer, and the use of PDE9A as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of prostate cancer, in particular hormone-resistant prostate cancer.

Phosphodiesterase 9A as prostate cancer marker

The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive prostate cancer.

Phosphodiesterase 4D7 as marker for malignant, hormone-sensitive prostate cancer

The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer, as well as a pharmaceutical composition comprising a compound directly stimulating or modulating the activity of PDE4D7, a compound indirectly stimulating or modulating the activity of PDE4D7, the PDE4D7 protein or a biologically active equivalent thereof, a nucleic acid encoding and expressing PDE4D7, a miRNA inhibitor specific for PDE4D7 miRNAs, a demethylation agent and/or a phosphodiesterase displacement factor.

Phosphodiesterase 4D7 as prostate cancer marker

Tagging of Histidine in polypeptides with arylboronic acid tagging reagents for identifying proteins in a sample by isolating and identifying Histidine-comprising peptides from one protein sample or a pool of protein samples. Databases of Histidine-including peptides from in silico cleaved proteins are uses in the identification of proteins.

Use of arylboronic acids in protein labelling

An improved radiation therapy planning procedure is suggested. The procedure comprises the steps of specifying and determining the absolute grade of cell degeneracy by in-vitro tests, whereby marker(s) indicative for specific cell degeneracy are detected and quantified, establishing a biology-based segmentation of areas with similar grade of relative cell degeneracy and applying the absolute grade of cell degeneracy to the biology-based segmentation data, thereby establishing an improved radiation therapy planning procedure. Moreover, the present invention suggests a system for an improved radiation therapy planning procedure and its use in procedures of diagnosis and/or therapy management of cancer.

Radiation therapy flanning procedure

An electrical component having a functional unit which is secured to a header and which generates or is sensitive to sound, and having terminal elements which are mechanically secured to the header and electrically and acoustically coupled to the functional unit and which project through holes in the header onto the side of the header remote from the functional unit and which have a modulus of elasticity of E >50 MPa, in which the terminal elements are partially encased in a viskoelastic material having a modulus of elasticity of E <10 MPa. By encasing the terminal elements in a viskoelastic material, effective sound-damping can be produced. Furthermore, the invention relates to a process for manufacturing the component.

Electrical component and process for the manufacture thereof

Apparatus and process for cooling foam products

The invention pertains to a device for the cooling of edible foams, where a cooling or freezing system for pre-freezing of the foam is directly outlet-connected to an aeration system, a motor driven extruder device designed as combined deep freezing and transport device is outlet-connected to the cooling and freezing system, in which the pre-frozen foam can be cooled down to storage temperature, and the aeration device, the cooling or freezing system and the extruder device are connected together by means of pipes. The device of the present invention is characterized in that the extruder device has at least one double screw system with two screws positioned parallel to each other with their rotational axes. The lands of the screws of the double screw system scrape against the inner cylinder mantle surface of the housing surrounding it. The threads of the second screw are centered between the threads of the first screw and an increased spacing of the rotational axes of the screws is created, so that the front side of the screw thread of the other screw facing the surface of the cylinder mantle of each screw, has a radial distance from it. The lands of the screws with the surface of the cylinder mantle of the screws and of the inner surface of the cylinder mantle of the housing bounds an extremely flat screw channel.

Device for cooling of fluids and edible foams

Growing community of inventors

Brueggen, Germany

Ralf Hoffmann